A Study Investigating the Pharmacokinetic and Pharmacodynamic Properties and Safety and Tolerability of NNC0471-0119 H When Administered as Bolus in a Continuous Subcutaneous Insulin Infusion Regimen in Participants With Type 2 Diabetes
Latest Information Update: 29 Jul 2025
At a glance
- Drugs NNC 0471-0119 (Primary) ; Insulin aspart
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 29 Jul 2025 New trial record